Immunogenic　photodynamic　therapy　(PDT)　has　the　potential　to　moderate　the　shortfalls　of　cancer　immunotherapy.　However,　its　efficacy　is　severely　limited　particularly　because　of　the　lack　of　optimal　photosensitizers　and　smart　delivery　processes　and　the　inherent　shortcomings　of　PDT　(e.g.,　hypoxia　resistance).　Here,　we　demonstrate　a　clinically　promising　approach　that　utilizes　a　water-soluble　phthalocyanine　derivative　(PcN4)　concomitantly　delivered　with　a　hypoxia-activated　prodrug　(AQ4N)　to　amplify　the　effect　of　PDT　and　enhance　cancer　immunotherapy.　After　intravenous　injection,　PcN4　selectively　interacted　with　endogenous　albumin　dimers　and　formed　supramolecular　complexes,　providing　a　facile　and　green　approach　for　tumor-targeted　PDT.　The　concomitant　delivery　of　AQ4N　overcame　the　limitations　of　hypoxia　in　PDT　and　improved　the　antitumor　activity　of　PDT.　Treatment　with　PcN4-mediated　and　AQ4N-amplified　PDT　almost　completely　eradicated　sizable　primary　tumors　in　a　triple-negative　breast　cancer　model　and　significantly　activated　CD8(+)　T　cells.　As　the　majority　of　tumor　infiltrating　CD8(+)　T　cells　were　both　PD-1-　and　TIM3-positive,　additional　combination　therapy　using　PD-L1/PD-1　pathway　blockade　was　warranted.　After　combination　with　immune　checkpoint　blockade　treatment,　an　enhanced　abscopal　effect　was　achieved　in　both　distant　and　metastatic　tumors.